{"drugs":["Mozobil","Plerixafor"],"mono":{"0":{"id":"929249-s-0","title":"Generic Names","mono":"Plerixafor"},"1":{"id":"929249-s-1","title":"Dosing and Indications","sub":[{"id":"929249-s-1-4","title":"Adult Dosing","mono":"<b>Harvesting of peripheral blood stem cells, In patients with non-Hodgkin's lymphoma and multiple myeloma:<\/b> 0.24 mg\/kg (actual body weight) subQ approximately 11 hr prior to initiation of apheresis for up to 4 consecutive days; administer granulocyte-colony stimulating factor (G-CSF) 10 mcg\/kg via subQ bolus or continuous infusion once daily in the morning for 4 days prior to the first evening dose of plerixafor, and on each day prior to apheresis; MAX dose of 40 mg\/day "},{"id":"929249-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"929249-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> CrCl less than or equal to 50 mL\/min, 0.16 mg\/kg SubQ once daily; MAX dose of 27 mg\/day<\/li><li><b>obesity:<\/b> the dose should not exceed that of a 160 kg patient (40 mg\/day if CrCl is greater than or equal to 50 mL\/min and 27 mg\/day if CrCl less than or equal to 50 mL\/min<\/li><\/ul>"},{"id":"929249-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Harvesting of peripheral blood stem cells, In patients with non-Hodgkin's lymphoma and multiple myeloma<br\/>"}]},"3":{"id":"929249-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929249-s-3-9","title":"Contraindications","mono":"hypersensitivity to plerixafor <br\/>"},{"id":"929249-s-3-10","title":"Precautions","mono":"<ul><li>anaphylactic shock has been reported<\/li><li>hypersensitivity reactions, serious, life-threatening and including anaphylactic-type reactions, have been reported; monitoring recommended<\/li><li>leukemia; may mobilize leukemic cells and contaminate the apheresis product; use not recommended<\/li><li>leukocytosis has been reported; monitoring recommended<\/li><li>renal impairment, moderate and severe (CrCl 50 mL\/min or less); dose reduction recommended<\/li><li>thrombocytopenia has been; monitoring recommended during apheresis<\/li><li>women of childbearing potential; risk of fetal harm; avoid pregnancy<\/li><li>report suspected adverse reactions to the US Food and Drug Administration (FDA) at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929249-s-3-11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"929249-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"929249-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (34%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (37%), Nausea (34%), Vomiting (10%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (13%)<\/li><li><b>Neurologic:<\/b>Dizziness (11%), Headache (22%)<\/li><li><b>Other:<\/b>Fatigue (27%)<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<br\/>"},"6":{"id":"929249-s-6","title":"Drug Name Info","sub":{"0":{"id":"929249-s-6-17","title":"US Trade Names","mono":"Mozobil<br\/>"},"2":{"id":"929249-s-6-19","title":"Class","mono":"Hematopoietic<br\/>"},"3":{"id":"929249-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929249-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929249-s-7","title":"Mechanism Of Action","mono":"Plerixafor is a hematopoietic stem cell mobilizer which inhibits the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1-alpha (SDF-1-alpha) which results in leukocytosis and elevations in circulating hematopoietic progenitor cells.<br\/>"},"8":{"id":"929249-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"929249-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 0.3 L\/kg<\/li><li>Protein binding: up to 58%<\/li><\/ul>"},"3":{"id":"929249-s-8-26","title":"Excretion","mono":"Renal: (subQ, healthy adults with normal renal function), 70% unchanged <br\/>"},"4":{"id":"929249-s-8-27","title":"Elimination Half Life","mono":"Healthy volunteers: 3 to 5 hrs <br\/>"}}},"9":{"id":"929249-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>inspect vial for particulate matter and discoloration prior to administration; do not use if particulate matter present or solution is discolored<\/li><li>calculate dose based on patient's actual body weight (up to 160 kg)<\/li><li>administer approximately 11 hr prior to initiation of apheresis for up to 4 consecutive days<\/li><li>administer daily morning doses of granulocyte-colony stimulating factor (G-CSF) 10 micrograms\/kilogram via subcutaneous bolus or continuous infusion for 4 days prior to the first evening dose of plerixafor and on each day prior to apheresis<\/li><\/ul>"},"10":{"id":"929249-s-10","title":"Monitoring","mono":"<ul><li>improvement in CD34+ cell mobilization outcomes, including increase in peripheral blood CD34+ cell count, indicates efficacy<\/li><li>WBC and platelet counts<\/li><li>signs and symptoms of hypersensitivity; during and for at least 30 minutes after administration until clinically stable<\/li><\/ul>"},"11":{"id":"929249-s-11","title":"How Supplied","mono":"<b>Mozobil<\/b><br\/>Subcutaneous Solution: 20 MG\/ML<br\/>"},"13":{"id":"929249-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause splenic rupture. Advise patient to report left upper abdominal, scapular, or shoulder pain.<\/li><li>Drug may cause injection site reactions, headache, arthralgia, dizziness, vomiting, diarrhea, nausea, and fatigue.<\/li><li>Instruct patient to report signs and symptoms of systemic reaction (urticaria, periorbital swelling, dyspnea, hypoxia).<\/li><li>Instruct patient to report signs and symptoms of vasovagal reaction (orthostatic hypotension, syncope).<\/li><\/ul>"}}}